BACKGROUND: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. OBJECTIVE: To develop consensus statements for all domains of DAT. DESIGN, SETTING, AND PARTICIPANTS: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review ...
Objective: To present a summary of the 2020 version of the European Association of Urology (EAU)-Eur...
BackgroundInnovations in treatments, imaging, and molecular characterisation in advanced prostate ca...
Active surveillance (AS) is broadly described as a management option for men with low-risk prostate ...
Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient s...
Background There is uncertainty in deferred active treatment (DAT) programmes, regarding patient se...
Deferred active treatment (DAT) strategies, including active surveillance and active monitoring, are...
Objective: To present a summary of the 2016 version of the European Association of Urology (EAU) - ...
BackgroundActive surveillance (AS) is a management option for men diagnosed with lower risk prostate...
BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate ...
BACKGROUND: In advanced prostate cancer (APC), successful drug development as well as advances in im...
In the past decade active surveillance (AS) of men with localized prostate cancer has become an incr...
Background: In advanced prostate cancer (APC), successful drug development as well as advances in im...
OBJECTIVES: To develop a consensus statement on current best practice of active surveillance (AS) in...
Objective To present a summary of the 2016 version of the European Association of Urology (EAU) - E...
Objective: To present a summary of the 2020 version of the European Association of Urology (EAU)-Eur...
Objective: To present a summary of the 2020 version of the European Association of Urology (EAU)-Eur...
BackgroundInnovations in treatments, imaging, and molecular characterisation in advanced prostate ca...
Active surveillance (AS) is broadly described as a management option for men with low-risk prostate ...
Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient s...
Background There is uncertainty in deferred active treatment (DAT) programmes, regarding patient se...
Deferred active treatment (DAT) strategies, including active surveillance and active monitoring, are...
Objective: To present a summary of the 2016 version of the European Association of Urology (EAU) - ...
BackgroundActive surveillance (AS) is a management option for men diagnosed with lower risk prostate...
BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate ...
BACKGROUND: In advanced prostate cancer (APC), successful drug development as well as advances in im...
In the past decade active surveillance (AS) of men with localized prostate cancer has become an incr...
Background: In advanced prostate cancer (APC), successful drug development as well as advances in im...
OBJECTIVES: To develop a consensus statement on current best practice of active surveillance (AS) in...
Objective To present a summary of the 2016 version of the European Association of Urology (EAU) - E...
Objective: To present a summary of the 2020 version of the European Association of Urology (EAU)-Eur...
Objective: To present a summary of the 2020 version of the European Association of Urology (EAU)-Eur...
BackgroundInnovations in treatments, imaging, and molecular characterisation in advanced prostate ca...
Active surveillance (AS) is broadly described as a management option for men with low-risk prostate ...